title: Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I.
abstract: Tolcapone is a potent catechol-O-methyltransferase inhibitor that prolongs the plasma half-life of levodopa. This multicenter, double-blind, placebo-controlled study used two 10-hour clinical evaluations to compare the efficacy and safety of three doses of tolcapone (50, 200, and 400 mg tid) with placebo in patients with Parkinson's disease (PD) experiencing motor fluctuations from levodopa/carbidopa. One hundred fifty-one patients completed the study. Clinical evaluations lasting 10 hours were performed on day -1 and day 42 using United Parkinson's Disease Rating Scale motor subscale and "on/off" and dyskinesia assessments every 30 minutes. Tolcapone significantly reduced "off" time an average of 40% and increased total "on" time by about 25% at all dose levels, as compared to placebo treatment. Levodopa/carbidopa dosage and frequency were significantly reduced. Tolcapone was well tolerated, with patients experiencing typical dopaminergic side effects that could be reduced or eliminated by lowering levodopa/carbidopa dosages. Tolcapone was effective at prolonging the clinical benefit of levodopa and reducing total levodopa requirements in PD patients with motor fluctuations.
authors.affiliation: Section of Movement Disorders, Barrow Neurological Institute, Phoenix, AZ 85013, USA.
authors.forename: M C
authors.initials: MC
authors.lastname: Kurth
authors.forename: C H
authors.initials: CH
authors.lastname: Adler
authors.forename: M S
authors.initials: MS
authors.lastname: Hilaire
authors.forename: C
authors.initials: C
authors.lastname: Singer
authors.forename: C
authors.initials: C
authors.lastname: Waters
authors.forename: P
authors.initials: P
authors.lastname: LeWitt
authors.forename: D A
authors.initials: DA
authors.lastname: Chernik
authors.forename: E E
authors.initials: EE
authors.lastname: Dorflinger
authors.forename: K
authors.initials: K
authors.lastname: Yoo
mesh_terms: D000368:Aged; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D001577:Benzophenones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009068:Movement / Q000187:drug effects*; D009596:Nitrophenols; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology*; D010919:Placebos; D000077867:Tolcapone; D016896:Treatment Outcome
chemical_list: D000978:Antiparkinson Agents; D001577:Benzophenones; D009596:Nitrophenols; D010919:Placebos; D007980:Levodopa; D000077867:Tolcapone